News
18h
TipRanks on MSNAbbVie and Genmab’s Promising Study on Epcoritamab for Non-Hodgkin LymphomaThe study involves testing epcoritamab, administered subcutaneously, in combination with oral and intravenous anti-neoplastic agents. These include drugs like lenalidomide, ibrutinib, and polatuzumab ...
20h
Zacks Investment Research on MSNLilly Down More Than 15% in a Year: Time to Buy, Sell or Hold?Eli Lilly and Company’s LLY stock has declined 15.7% in the past year. The first-quarter earnings miss, guidance cut and some ...
The deal hands AbbVie a drug that’s shown early promise in multiple myeloma and may be useful treating other cancers and ...
Interleukin-2 (IL-2) inhibitors are immunosuppressive agents that block the activity of IL-2, a cytokine involved in the activation and proliferation ...
The cannabinoid agonist market is gaining momentum due to expanding medical cannabis legalization and growing clinical validation for its use in chro ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results